Extended Data Fig. 6: Clinical activity of belvarafenib.
From: ARAF mutations confer resistance to the RAF inhibitor belvarafenib in melanoma
a, Tumour responses in the dose-escalation phase. Best percentage changes in size of target lesions from baseline and specific genetic mutations in each evaluable patient are shown. Others include: NSCLC, bladder, GIST, and sarcoma. Two patients with only non-target lesions at baseline were excluded. b, Tumour response in efficacy-evaluable patients from the dose-escalation and dose-expansion phases. DCR, disease control rate; PFS, progression-free survival; DOR, duration of response; NE, not estimable. Note that BORR (%) = (number of subjects with best overall response as complete or partial response/total number of subjects) × 100. ORR (%) = (number of subjects with confirmed best overall response as complete or partial response/total number of subjects) × 100. DCR (%) = (number of subjects with best overall response as complete or partial response or stable disease/total number of subjects) × 100. c–f, Progression-free survival plot of all patients (c) and patients with NRAS-mutant melanoma (d) in dose-escalation phase, and all patients (e) and patients with NRAS-mutant melanoma (f) in dose-expansion phase. g, Patients with NRAS-mutant melanoma with previous immunotherapy treatments. BOR, best overall response; CPI, check-point inhibitor; PD, progression of disease; PR, partial response; SD, stable disease; uPR, unconfirmed partial response. Confirmed partial response is claimed only if patient achieved partial or complete responses at a subsequent time point as specified in the protocol. h, Patients with BRAFV600E-mutant melanoma and CRC with previous BRAFV600E inhibitor treatments. i, j, Responses and treatment durations of patients in dose-escalation (i) and dose-expansion (j) phases. In the dose-escalation and dose-expansion phases, one patient with both BRAF and NRAS mutations enrolled in each phase as indicated in the swimmer plot.
